NCT04965831View on ClinicalTrials.gov

Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

March 1, 2023

Study Completion Date

May 1, 2026

Conditions
Lung Adenocarcinoma
Interventions
DRUG

Furmonertinib

Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.

Sponsors
All Listed Sponsors
collaborator

Allist Pharmaceuticals, Inc.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT04965831 - Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) | Biotech Hunter | Biotech Hunter